In this study, we identified the potassium adduct of the phosphatidyl choline PC(36:1), and heme B, a marker for erythroid redifferentiation of CML cells, as markers of BCR-ABL potency that could be used for IC50 determination. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.